Bicalutamide plus Anastrozole for the Treatment of Gonadotropin-Independent Precocious Puberty in Boys with Testotoxicosis: A Phase II, Open-Label Pilot Study (BATT)

@inproceedings{Reiter2010BicalutamidePA,
  title={Bicalutamide plus Anastrozole for the Treatment of Gonadotropin-Independent Precocious Puberty in Boys with Testotoxicosis: A Phase II, Open-Label Pilot Study (BATT)},
  author={Edward O. Reiter and Nelly Mauras and Ken Mccormick and Bindu Kulshreshtha and J A Amrhein and Francesco De Luca and Sandra Anaya O'Brien and Jon M Armstrong and Helena Melez{\'i}nkov{\'a}},
  booktitle={Journal of pediatric endocrinology \& metabolism : JPEM},
  year={2010}
}
ABSTRACT Objective: To evaluate the efficacy, tolerability, and pharmacokinetics of bicalutamide plus anastrozole in young males with testotoxicosis. Methods: This was a multicenter, open-label, single-arm, 12-month, Phase II pilot trial in 14 males (2-9 years) with testotoxicosis treated with bicalutamide (12.5, 25, 50, or 100 mg) and anastrozole (0.5 or 1 mg) daily. The primary outcome was change in growth rate. Results: At 1 year, the mean (standard deviation) change from baseline in growth… Expand
Central precocious puberty in a case of late-diagnosed familial testotoxicosis and long-term treatment monitoring
TLDR
The case of coexistent familial testotoxicosis and central precocious puberty induced by long-term androgen exposure in a patient aged 7.5 years, whose clinical symptoms started at the age of 4 years is presented. Expand
Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin‐releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty
TLDR
Long‐term treatment with antiandrogen, aromatase inhibitor, and GnRHa in boys with FMPP results in AH modestly below sex‐adjusted midparental height and within the range for adult males in the general population. Expand
Testotoxicosis: Report of Two Cases, One with a Novel Mutation in LHCGR Gene
TLDR
Two patients who presented with peripheral precocious puberty and an activating mutation in the LHCGR gene are reported, one with aFamily history and previously determined mutation and the other without family history and with a novel mutation, that were ineffective in slowing pubertal progression and bone age. Expand
Treatment and outcomes of precocious puberty: an update.
  • J. Fuqua
  • Medicine
  • The Journal of clinical endocrinology and metabolism
  • 2013
TLDR
Extended-release leuprolide acetate injections that indicate that the 11.25-mg dose may not provide full biochemical suppression but may clinically suppress signs of puberty, including the accelerated growth velocity and advanced skeletal maturation seen in CPP are published. Expand
Idiopathic gonadotropin-independent precocious puberty – is regular surveillance required?
  • V. Arya, J. Davies
  • Medicine
  • Journal of pediatric endocrinology & metabolism : JPEM
  • 2019
TLDR
This case highlights that GIPP with no definite underlying aetiology at diagnosis should be considered as a prodrome for GCTs, and regular radiological surveillance for earlier tumour identification is warranted. Expand
Treatment of Peripheral Precocious Puberty.
TLDR
Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive, and while the number of treated patients remains small, several successful therapeutic options for FMPP are available. Expand
Adult height in patients with familial male-limited precocious puberty and the role of an aromatase inhibitor in patient management
TLDR
Aromatase inhibitor therapy is associated with a positive height outcome in FMPP but the outcome with and without intervention is unpredictable and Clinicians need to be cautious when counselling families about the potential height outcome. Expand
Aromatase inhibitors for short stature in male children and adolescents.
BACKGROUND As a result of the essential role of oestrogens in epiphyseal closure, aromatase inhibitors have been trialled as an intervention to improve height outcomes in male children andExpand
Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents.
TLDR
Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in transgender male-to-female youth who are also ready to undergo physical transition. Expand
Strategies for maximizing growth in puberty in children with short stature.
  • N. Mauras
  • Medicine
  • Pediatric clinics of North America
  • 2011
TLDR
This class of drugs, if judiciously used for a window of time, offers promise as an adjunct treatment of growth delay in pubertal patients with GH deficiency, idiopathic short stature, testotoxicosis, and other disorders of growth. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 26 REFERENCES
Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia.
TLDR
Anastrozole is a potent aromatase inhibitor in adolescent males, with rapid absorption and slow elimination kinetics after oral dosing and breast reduction in the cohort; this deserves further study. Expand
The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome.
TLDR
Although it appears safe, anastrozole for 1 yr was ineffective in halting vaginal bleeding, attenuating rates of skeletal maturation, and linear growth in girls with MAS. Expand
An Open Label 12-Month Pilot Trial on the Effects of the Aromatase Inhibitor Anastrozole in Growth Hormone (GH)-Treated GH Deficient Adolescent Boys
TLDR
Anastrozole treatment potently decreases estrogen concentrations in adolescent males with GHD while allowing normal virilization, without deleterious effects on body composition, plasma lipids, bone metabolism or the tempo of puberty. Expand
Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy.
TLDR
Administration of ketoconazole may be a satisfactory treatment for precocious puberty in boys and possibly for other conditions characterized by androgen excess, preliminary data suggest. Expand
Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset.
TLDR
It is concluded that long term treatment with spironolactone, testolact one, and, after central puberty, deslorelin normalizes the growth rate and bone maturation and improves the predicted height in boys with familial male-limited precocious puberty. Expand
Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial.
TLDR
In patients with pubertal gynecomastia, no significant difference in the percentage of patients with a 50% or greater reduction in total breast volume, as calculated from ultrasonography measurements, was demonstrated between the anastrozole and placebo groups. Expand
Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty.
TLDR
It is concluded that ketoconazole is an efficient and well tolerated long-term treatment of familial male-limited precocious puberty that should be proposed as a first line therapy. Expand
Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years.
TLDR
Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2-3 yr, and offers an alternative in promoting growth in GH-deficient boys in puberty. Expand
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
TLDR
Bicalutamide 150-mg monotherapy provides a similar survival outcome to castration in previously untreated patients with nonmetastatic advanced prostate cancer and confers statistically significant benefits over castration with respect to sexual interest and physical capacity. Expand
Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin.
TLDR
The addition of deslorelin to the combined therapy appears to restore the control of puberty in this setting, as the rise in gonadotropin levels during central activation of hypothalamic LHRH secretion in boys with familial male precocious puberty causes a partial escape from the combined effect of spironolact one and testolactone. Expand
...
1
2
3
...